Trial Profile
A Phase I, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs C4X 3256 (Primary)
- Indications Opioid-related disorders; Substance-related disorders
- Focus Adverse reactions; First in man
- Sponsors Indivior
- 09 Jun 2022 According to an Indivior media release, data from this trial will be presented at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD), 2022.
- 14 Apr 2021 Status changed from recruiting to completed.
- 11 Feb 2021 Planned End Date changed from 12 Feb 2021 to 6 May 2021.